Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

861. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. Full Text available with Trip Pro

A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. Radical prostatectomy is widely used in the treatment of early prostate cancer. The possible survival benefit of this treatment, however, is unclear. We conducted a randomized trial to address this question.From October 1989 through February 1999, 695 men with newly diagnosed prostate cancer in International Union against Cancer clinical stage T1b, T1c, or T2 were randomly assigned to watchful (...) waiting or radical prostatectomy. We achieved complete follow-up through the year 2000 with blinded evaluation of causes of death. The primary end point was death due to prostate cancer, and the secondary end points were overall mortality, metastasis-free survival, and local progression.During a median of 6.2 years of follow-up, 62 men in the watchful-waiting group and 53 in the radical-prostatectomy group died (P=0.31). Death due to prostate cancer occurred in 31 of 348 of those assigned to watchful

2002 NEJM Controlled trial quality: predicted high

862. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. (Abstract)

survival 79% (72-86) and 94% (90-98).Immediate androgen suppression with an LHRH analogue given during and for 3 years after external irradiation improves disease-free and overall survival of patients with locally advanced prostate cancer. (...) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. We did a randomised phase III trial comparing external irradiation alone and external irradiation combined with an analogue of luteinising-hormone releasing hormone (LHRH) to investigate the added value of long-term androgen suppression in locally advanced prostate cancer.Between 1987 and 1995, 415 patients were randomly

2002 Lancet Controlled trial quality: predicted high

863. Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult. Full Text available with Trip Pro

Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult. Recruitment to randomised trials is often difficult, and many important trials are not mounted because recruitment is thought to be "impossible."Controversial ProtecT (prostate testing for cancer and treatment) trial embedded within qualitative (...) research.Screening for prostate cancer is hotly debated, and evidence from trials about the effectiveness of treatments (surgery, radiotherapy, and monitoring) is lacking. Mounting a treatment trial is controversial because of past failures and concerns that differences in complications of treatment but not survival make randomisation unacceptable to patients and clinicians, particularly for a trial including monitoring.In-depth interviews explored interpretation of study information. Audiotape recordings

2002 BMJ Controlled trial quality: uncertain

864. Treating prostate cancer with brachytherapy

Treating prostate cancer with brachytherapy Treating prostate cancer with brachytherapy Treating prostate cancer with brachytherapy Johansen T B, Dahl O, Heikkila R, Hoisaeter P A, Klepp O, Olsen D R, Waehre H Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Johansen T B, Dahl O, Heikkila R, Hoisaeter P A, Klepp O, Olsen D R, Waehre H (...) . Treating prostate cancer with brachytherapy. Oslo: The Norwegian Knowledge Centre for the Health Services (NOKC) 2002 Authors' objectives This report assesses the clinical effectiveness and cost effectiveness of prostate brachytherapy compared with radical prostatectomy, external beam radiation or watchful waiting. Authors' conclusions overall or cancer free survival: In most cases prostate cancer progress slowly; 5-year survival for localised prostate cancer is around 80%. None of the included studies

2002 Health Technology Assessment (HTA) Database.

865. Screening for prostate cancer

Screening for prostate cancer Screening for prostate cancer Screening for prostate cancer Harris R, Lohr K N, Beck R, Fink K, Godley P, Bunton A J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Harris R, Lohr K N, Beck R, Fink K, Godley P, Bunton A J. Screening for prostate cancer. Rockville: Agency for Healthcare Research and Quality (...) (AHRQ). Preventive Services Task Force Systematic Evidence Review No. 16. 2002 Authors' objectives To examine the evidence of the benefits and harms of screening and earlier treatment in reducing prostate cancer mortality and to assist the US Preventive Services Task Force in making recommendations on this topic. Authors' conclusions We are unable to determine the net benefit of screening because we cannot establish the presence and, if present, the magnitude of benefit from screening. We can

2002 Health Technology Assessment (HTA) Database.

866. [The effectiveness and safety of different forms of treating prostate cancer]

[The effectiveness and safety of different forms of treating prostate cancer] La efectividad y seguridad de los distintos tratamientos del cancer de prostata [The effectiveness and safety of different forms of treating prostate cancer] La efectividad y seguridad de los distintos tratamientos del cancer de prostata [The effectiveness and safety of different forms of treating prostate cancer] Rueda J R, Lecumberri D, Casquero F, Pereira G, Escobal V Citation Rueda J R, Lecumberri D, Casquero F (...) , Pereira G, Escobal V. La efectividad y seguridad de los distintos tratamientos del cancer de prostata. [The effectiveness and safety of different forms of treating prostate cancer] Vitoria-Gasteiz: Basque Office for Health Technology Assessment (OSTEBA). D-02-06. 2002 Authors' objectives

This review aims to determine the effectiveness and safety of the different therapeutic options available for prostate cancer.

Final publication URL Indexing Status Subject indexing assigned by CRD MeSH

2002 Health Technology Assessment (HTA) Database.

867. The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 prostate cancer

The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 prostate cancer The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 prostate cancer The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 prostate cancer Brundage M, Lukka H, Crook J, Warde P, Bauman G, Catton C, Markman B R, Charette M, Genitourinary Cancer Disease Site Group CRD summary This review evaluated the effects of conformal radiotherapy (CR (...) the benefits of dose escalation when CR is used. Funding Cancer Care Ontario; Ontario Ministry of Health and Long-term Care. Bibliographic details Brundage M, Lukka H, Crook J, Warde P, Bauman G, Catton C, Markman B R, Charette M, Genitourinary Cancer Disease Site Group. The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 prostate cancer. Cancer Care Ontario Practice Guidelines Initiative 2002. Available at: Accessed April, 2014 This paper is produced by Cancer Care Ontario

2002 DARE.

868. Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis

Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2002 DARE.

869. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan

conclusions The effectiveness analysis showed that positive bone scans were quite rare in patients with serum PSA levels less than or equal to 10 ng/mL, especially those patients with a tumour of Gleason Grade less than or equal to 2. Modelling A decision tree model was constructed in order to simulate the natural history and clinical management (mainly based on monitoring) of a cohort of patients with newly diagnosed prostate cancer. Cumulative costs and expected disease-specific survival rates were (...) , Ichihara K, Yonese J, Koizumi M, Nakashima J, Fujii H. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan. Cancer 2002; 94(4): 964-972 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Adult; Aged; Aged, 80 and over; Biopsy, Needle; Bone Neoplasms /diagnosis /radionuclide imaging /secondary; Carcinoma /pathology; Decision Making; Humans; Male; Middle Aged

2002 NHS Economic Evaluation Database.

870. Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer

for 1 month, starting 1 week before the first dose of goserelin. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with histologically proven locally advanced prostate cancer (cT3-4, N0-2, M0), according to the tumour-node-metastasis classification system of the International Union against Cancer. The patients were younger than 80 years of age and had not undergone any earlier treatment for prostate cancer (...) . Patients with a prior malignant disease (except for treated basal-cell carcinoma of the skin) and those with evidence of distant metastases were excluded. Setting The setting was a hospital. The economic study was carried out in France. Dates to which data relate The effectiveness evidence and resource use data were derived from a study published in 1997 (see Other Publications of Related Interest). The data were collected between 1987 and 1995. The price year was 1998. Source of effectiveness data

2002 NHS Economic Evaluation Database.

871. Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening

Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening Ellison L, Cheli C D, Bright S, Veltri R W, Partin A W Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of prostate-specific antigen (PSA) for population-based prostate cancer screening. Five strategies were identified. These were total PSA (tPSA) 4.0 ng/mg, free PSA/tPSA (f/tPSA), and complexed PSA (cPSA) 3.8, 3.4, and 3.0 ng/mg. Type of intervention Screening. Economic study

2002 NHS Economic Evaluation Database.

872. Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. (Abstract)

Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. A positive association between latitude and prostate cancer mortality has been interpreted to indicate that ultraviolet radiation (UVR) protects against development of this cancer. We aimed to examine this hypothesis. We compared exposure between 210 cases and 155 controls. Childhood sunburn (odds ratio 0.18, 95% CI 0.08-0.38), regular foreign holidays(0.41, 0.25-0.68), sunbathing (...) score (0.83, 0.76-0.89), and low exposure to UVR (3.03, 1.59-5.78) were associated with development of prostate cancer. Furthermore, cases with low UVR exposure developed cancer at a younger median age (67.7 years, IQR 61.5-74.6) than cases with higher exposure (72.1 years, 67.5-76.4); p=0.006. These findings are compatible with UVR having a protective role against prostate cancer.

2001 Lancet

873. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. (Abstract)

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Prostate carcinoma is linked to osteoblastic metastasis. We therefore investigated the value of bone-targeted consolidation therapy in selected patients with advanced androgen-independent carcinoma of the prostate.103 patients received induction chemotherapy, consisting of ketoconazole and doxorubicin alternating with estramustine and vinblastine. After two or three cycles (...) with stable or responding advanced androgen-independent carcinoma of the prostate after induction chemotherapy, improved overall survival.

2001 Lancet Controlled trial quality: uncertain

874. A quantitative analysis of the costs and benefits of prostate cancer screening Full Text available with Trip Pro

, refer to the need for randomised controlled trials (including the analysis of serial screening over a longer term) to appropriately quantify the costs and benefits of prostate cancer screening. Source of funding None stated. Bibliographic details Benoit R M, Gronberg H, Naslund M J. A quantitative analysis of the costs and benefits of prostate cancer screening. Prostate Cancer and Prostatic Diseases 2001; 4(3): 138-145 PubMedID DOI Other publications of related interest Richie JP, Catalona WJ (...) A quantitative analysis of the costs and benefits of prostate cancer screening A quantitative analysis of the costs and benefits of prostate cancer screening A quantitative analysis of the costs and benefits of prostate cancer screening Benoit R M, Gronberg H, Naslund M J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed

2001 NHS Economic Evaluation Database.

875. Brachytherapy in early localized prostate cancer

Brachytherapy in early localized prostate cancer Brachytherapy in early localized prostate cancer Brachytherapy in early localized prostate cancer Comite d' Evaluation et de Diffusion des Innovations Technologiques Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Comite d' Evaluation et de Diffusion des Innovations Technologiques (...) . Brachytherapy in early localized prostate cancer. Paris: Comite d´Evaluation et de Diffusion des Innovations Technologiques (CEDIT). 01.06. 2001 Authors' objectives This report aims to assess the wider application of brachytherapy in the treatment of forms of early localized prostate cancer. Authors' conclusions The CEDIT is of the opinion that there are too many reservations regarding brachytherapy as a treatment for early localized prostate cancer in terms of exact indications, methodology, effectiveness

2001 Health Technology Assessment (HTA) Database.

876. Brachytherapy for localised prostate cancer

Brachytherapy for localised prostate cancer Brachytherapy for localised prostate cancer Brachytherapy for localised prostate cancer Patterson J Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Patterson J. Brachytherapy for localised prostate cancer. London: Bazian Ltd (Editors), Wessex Institute for Health Research and Development, University of Southampton 2001 (...) : 9 Authors' objectives This study aims to assess the effects of brachytherapy versus other radiotherapy, radical prostatectomy, watchful waiting or drug treatments among men with localised prostate cancer. Authors' conclusions We found a lack of reliable evidence for effects of brachytherapy in men with localised non-metastatic prostate cancer. Particular difficulties exist in this therapeutic area, since the treatments are still evolving and may be used in many different combinations. Long

2001 Health Technology Assessment (HTA) Database.

877. Treatment of localised prostate cancer

Treatment of localised prostate cancer Treatment of localised prostate cancer Treatment of localised prostate cancer L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES). Treatment of localised prostate cancer (...) . Paris: L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) 2001: 4 Authors' objectives This report reviews the available evidence on the the efficacy and safety of treatment for localised prostate cancer. Authors' conclusions When a decision has been taken to treat localised prostate cancer, there is no formal evidence to support the superiority of either radical prostatectomy or localised external radiotherapy, or to justify the use of one form of treatment rather than another

2001 Health Technology Assessment (HTA) Database.

878. Cryoablation for the primary treatment of clinically localized prostate cancer

treatment of clinically localized prostate cancer. Comparisons will be made to evidence on outcomes and adverse effects of conformal external beam radiotherapy and nerve-sparing radical prostatectomy for clinically localized prostate cancer. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Cryosurgery; Prostatic Neoplasms Language Published English Country of organisation United States Address for correspondence BlueCross BlueShield Association, Technology Evaluation Center, 225 (...) Cryoablation for the primary treatment of clinically localized prostate cancer Cryoablation for the primary treatment of clinically localized prostate cancer Cryoablation for the primary treatment of clinically localized prostate cancer BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. The BlueCross BlueShield Association Technology

2001 Health Technology Assessment (HTA) Database.

879. Cryotherapy for prostatic cancer

to assess the effects of cryotherapy compared with conventional treatments in men with prostate cancer. Authors' conclusions We found no evidence that cryosurgery improved clinical outcomes. Weak evidence from methodologically flawed case series suggested that cryosurgery may reduce biochemical and histological markers of disease from pre-intervention levels, although the clinical importance of such a reduction is unclear. We found no controlled trials comparing cryosurgery with other treatments (...) Cryotherapy for prostatic cancer Cryotherapy for prostatic cancer Cryotherapy for prostatic cancer Foster K N Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Foster K N. Cryotherapy for prostatic cancer. London: Bazian Ltd (Editors), Wessex Institute for Health Research and Development, University of Southampton 2001: 10 Authors' objectives This study aims

2001 Health Technology Assessment (HTA) Database.

880. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. (Abstract)

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. Treatment with a gonadotropin-releasing hormone agonist decreases bone mineral density and increases the risk of fracture in men with prostate cancer. We conducted a controlled study of the prevention of osteoporosis in men undergoing treatment with a gonadotropin-releasing hormone agonist.In a 48-week, open-label study, we randomly assigned 47 men with advanced or recurrent prostate cancer and no bone (...) = 0.003), total hip (P=0.005), and trabecular bone of the lumbar spine (P=0.02).Pamidronate prevents bone loss in the hip and lumbar spine in men receiving treatment for prostate cancer with a gonadotropin-releasing hormone agonist.

2001 NEJM Controlled trial quality: uncertain